Jafron Biomedical Co

Jafron Biomedical Co EV/EBITDA

The EV/EBITDA (Enterprise Value to EBITDA) of Jafron Biomedical Co (300529.SZ) as of Nov 13, 2026 is 22.92. In the previous year, EV/EBITDA (Enterprise Value to EBITDA) was 13.17 — a change of 74.06% (higher).

EV/EBITDA

22.92

YoY

74.06%

Last updated:

EV/EBITDA (Enterprise Value to EBITDA) of Jafron Biomedical Co is 2025 22.92 . EV/EBITDA (Enterprise Value to EBITDA) of Jafron Biomedical Co was 2024 13.17 . It decreases by 74.06% higher compared to the previous year.

The Jafron Biomedical Co EV/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBITDA
Date
EV/EBITDA
Jan 1, 2018
30.42 CNY
Jan 1, 2019
20.98 CNY
Jan 1, 2020
13.27 CNY
Jan 1, 2021
9.81 CNY
Jan 1, 2022
13.54 CNY
Jan 1, 2023
24.35 CNY
Jan 1, 2024
13.17 CNY
Jan 1, 2025
22.92 CNY
The Jafron Biomedical Co EV/EBITDA history
YEAREV/EBITDAYoY
22.92+74.06%
13.17-45.92%
24.35+79.86%
13.54+37.96%
9.81-26.07%
13.27-36.74%
20.98-31.03%
30.42-30.68%
43.88-30.12%
62.79-4.12%
65.49-25.82%
88.28—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Jafron Biomedical Co Stock analysis

What does Jafron Biomedical Co do? Jafron Biomedical Co., Ltd. generates revenue through the research, development, production, and sale of hemoperfusion products and medical equipment. The company offers a range of items including disposable hemoperfusion devices, hemoperfusion machines, disposable bilirubin adsorbers, the DX-10 blood purification machine, suture needles, and resins bandage. These products are utilized for treating conditions such as uremia, poisoning, severe liver diseases, autoimmune diseases, and multisystem organ failure. The primary customers for these medical solutions are hospitals across China, where the company’s products are applied in more than 3000 hospitals within 31 provinces. As a China-based company, Jafron Biomedical Co., Ltd. focuses on the design, manufacture, and distribution of biological materials and medical equipment to support healthcare providers in these regions. The company operates from its headquarters in Zhuhai, Guangdong, and supports its operations with a workforce of 3,003 full-time employees. By engaging in the full lifecycle of its products from research to sale, the firm serves the medical sector with specialized equipment for blood purification and related therapeutic needs. Jafron Biomedical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Jafron Biomedical Co stock

EV/EBITDA (Enterprise Value to EBITDA) of Jafron Biomedical Co is 22.92 in 2025.

EV/EBITDA (Enterprise Value to EBITDA) of Jafron Biomedical Co changed from 13.17 to 22.92, representing a 74.06% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/EBITDA (Enterprise Value to EBITDA) Jafron Biomedical Co since 2006 – with annual values, charts, and detailed analysis.

The EV/EBITDA ratio is a widely used valuation metric that compares a company's enterprise value to its EBITDA. It normalizes for differences in capital structure, taxation, and depreciation policies.

To evaluate EV/EBITDA (Enterprise Value to EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBITDA (Enterprise Value to EBITDA).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBITDA (Enterprise Value to EBITDA)'s Jafron Biomedical Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — Jafron Biomedical Co

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Jafron Biomedical Co